Live
- IPL 2025 Auction: Ravichandran Ashwin, Rachin Ravindra return to Chennai Super Kings
- Manipur: After over a week's closure, regular classes to resume in educational institutions
- Govt open to discuss all issues, says Kiren Rijiju on eve of Winter Session of Parliament
- Pakistan reports three new polio cases, 2024 tally reaches 55
- Multifold Increase in migratory bird population at TN bird sanctuary
- Archaka Maha Sabha in Jogulamba Gadwal District Highlights Key Demands for Priests' Welfare
- IPL 2025 Auction: Both Rahul and Starc are world-class players, says Delhi Capitals head coach Badani
- Committed to the Welfare of Brahmins - MLA Kuchukulla Rajesh Reddy
- MLA Shri Ganesh Participates in Maha Sudarshana Homam and Srinivasa Kalyanam in Secunderabad
- Terror hideout busted in J&K's Kupwara district
Axxelent receives its first US FDA EIR
Axxelent Pharma Science Private Limited (Axxelent) has received the first Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its oral solid dosage facility situated in Sri City SEZ, AP. US FDA officials inspected the facility during June 17-21.
Sri City : Axxelent Pharma Science Private Limited (Axxelent) has received the first Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its oral solid dosage facility situated in Sri City SEZ, AP. US FDA officials inspected the facility during June 17-21.
Co-founder and Chairman of Axxelent Jitesh Devendra said that they are very glad about the outcome of the first US FDA inspection for the oral solid dosage facility. The next step is to trigger the sterile facility with the qualification expected to complete by Q3 in the FY25. He said that they have a pipeline of around 45 projects in various phases across multiple geographies and dosage forms.
Axxelent, headquartered in Chennai is a speciality Pharma company offering various development and manufacturing capabilities in immediate and modified release oral dosage forms, oral liquids, semi-solids, injectables and ophthalmic.
